Ascletis Pharma Stock Today
| ASCLF Stock | USD 1.04 0.12 13.04% |
PerformanceGood
| Odds Of DistressAverage
|
Ascletis Pharma is trading at 1.04 as of the 19th of March 2025. This is a 13.04 percent increase since the beginning of the trading day. The stock's lowest day price was 1.04. Ascletis Pharma has 52 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. The company has 1.09 B outstanding shares. More on Ascletis Pharma
Moving together with Ascletis Pink Sheet
Moving against Ascletis Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Ascletis Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Ascletis Pharma [ASCLF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Small-Cap' category with a current market capitalization of 672.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascletis Pharma's market, we take the total number of its shares issued and multiply it by Ascletis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ascletis Pharma classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 1.09 B outstanding shares.
Ascletis Pharma has accumulated about 2.5 B in cash with (146.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ascletis Pharma Probability Of Bankruptcy
Ownership AllocationAscletis Pharma holds a total of 1.09 Billion outstanding shares. Ascletis Pharma shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.02 percent of Ascletis Pharma outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Ascletis Ownership Details
Ascletis Pharma Risk Profiles
| Mean Deviation | 7.13 | |||
| Standard Deviation | 21.63 | |||
| Variance | 467.67 | |||
| Risk Adjusted Performance | 0.1674 |
Ascletis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ascletis Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
Ascletis Pharma Corporate Management
| Jinzi Wu | Chairman Founder | Profile | |
| Ming CPA | Company Sec | Profile | |
| Yuemei Yan | Sr Operations | Profile | |
| John MBA | Chief Officer | Profile | |
| George Hill | Consultant Advisor | Profile | |
| Hejingdao Wu | Sr Director | Profile | |
| Handan He | Chief Officer | Profile |
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.